These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 21160478)
21. Case of Severe Hypertension and Nephrotic Range Proteinuria. Bursztyn M; Touyz RM; Laffer CL; Carey RM; Dominiczak AF Hypertension; 2018 Jun; 71(6):956-961. PubMed ID: 29610267 [No Abstract] [Full Text] [Related]
22. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876 [TBL] [Abstract][Full Text] [Related]
23. Nephrotic-range proteinuria in a patient with high renin hypertension: effect of treatment with an ACE-inhibitor. Docci D; Moscatelli G; Capponcini C; Baldrati L; Feletti C Am J Nephrol; 1992; 12(5):387-9. PubMed ID: 1489013 [TBL] [Abstract][Full Text] [Related]
24. Eplerenone's role in the management of complex cardiovascular disorders. Stewart Coats AJ; Shewan L Int J Cardiol; 2015 Dec; 200():1-2. PubMed ID: 26116081 [TBL] [Abstract][Full Text] [Related]
25. Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Sato A Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954 [TBL] [Abstract][Full Text] [Related]
26. Effect of captopril in nephrotic-range proteinuria due to renovascular hypertension. Martinez Vea A; García Ruiz C; Carrera M; Oliver JA; Richart C Nephron; 1987; 45(2):162-3. PubMed ID: 3550500 [No Abstract] [Full Text] [Related]
27. Does eplerenone have a future in the management of hypertension in Europe? Gosse P; Macfadyen RJ J Hum Hypertens; 2006 Nov; 20(11):829-32. PubMed ID: 16915301 [No Abstract] [Full Text] [Related]
29. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599 [No Abstract] [Full Text] [Related]
30. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T; Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242 [TBL] [Abstract][Full Text] [Related]
31. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747 [TBL] [Abstract][Full Text] [Related]
32. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone. Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746 [TBL] [Abstract][Full Text] [Related]
33. [Antihypertensive agents used as first line agents: beta-blockers under pressure]. Burnier M; Pechère A; Waeber B Rev Med Suisse; 2006 Sep; 2(78):2019-20. PubMed ID: 17019836 [No Abstract] [Full Text] [Related]
34. Eplerenone for gitelman syndrome in pregnancy. Morton A; Panitz B; Bush A Nephrology (Carlton); 2011 Mar; 16(3):349. PubMed ID: 21342329 [No Abstract] [Full Text] [Related]
35. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Zhou X; Ono H; Ono Y; Frohlich ED Am J Nephrol; 2004; 24(2):242-9. PubMed ID: 15031627 [TBL] [Abstract][Full Text] [Related]